5 Critical Differences Between Spravato and Ketamine for Treatment-Resistant Depression
For those battling treatment-resistant depression (TRD), finding effective therapies can feel like searching for a light switch in a pitch-black room. Two breakthrough treatments—Spravato (esketamine) and ketamine—have illuminated new paths of hope for patients who haven’t responded to traditional antidepressants. While these medications share similarities, understanding their crucial differences could determine which treatment offers the best chance for recovery.
At Spravato Treatment Centers of New Jersey, we specialize in utilizing FDA-approved Spravato therapy to help patients overcome persistent depression. Let’s explore the essential distinctions between these two promising treatments.
1. FDA Approval Status: The Regulatory Difference
The most significant difference between these treatments lies in their FDA approval status. Spravato (esketamine nasal spray) received FDA approval in 2019 specifically for treatment-resistant depression and depressive symptoms with suicidal thoughts. This approval followed rigorous clinical trials demonstrating both safety and efficacy.
In contrast, while ketamine shows promise for depression treatment, it remains FDA-approved only as an anesthetic. When used for depression, ketamine is prescribed “off-label,” meaning physicians are utilizing it for a purpose different from its original FDA-approved indication.
Key Point: Choosing an FDA-approved treatment like Spravato provides the assurance that the therapy has undergone extensive testing specifically for depression treatment, meeting strict standards for safety and effectiveness.
2. Chemical Composition: Similar But Distinct
While ketamine and Spravato are chemically related, they’re not identical. Ketamine is composed of two mirror-image molecules (enantiomers): R-ketamine and S-ketamine. Spravato contains only S-ketamine (esketamine), which research suggests binds more strongly to certain receptors in the brain.
This distinction means esketamine can potentially deliver therapeutic benefits at lower doses, which may reduce side effects while maintaining efficacy. The focused chemical composition of Spravato represents a refined approach to depression treatment.
3. Administration Method: Controlled vs. Variable
The administration method creates another significant difference between these treatments. Spravato is delivered as a nasal spray in a controlled clinical setting under medical supervision. After administration, patients remain under observation for at least two hours to monitor for potential side effects.
Ketamine for depression is typically administered as an intravenous (IV) infusion, requiring precise dosing and monitoring. While effective, this method necessitates medical staff with specialized training in IV administration.
For detailed information about the Spravato administration process and what to expect during treatment, visit our Spravato FAQ page.
4. Insurance Coverage: Financial Accessibility
The FDA approval of Spravato creates a significant advantage regarding insurance coverage. Many insurance providers now cover Spravato treatment for eligible patients with treatment-resistant depression, making this innovative therapy more financially accessible.
Since ketamine infusions for depression represent off-label use, insurance coverage remains limited, requiring many patients to pay out-of-pocket. This financial barrier can place ketamine therapy out of reach for numerous individuals who might benefit from treatment.
To learn more about Spravato costs and insurance coverage options, please review our comprehensive guide to Spravato costs and insurance.
5. Side Effect Profile: Important Considerations
Both treatments may cause side effects, but their profiles differ in important ways. Spravato’s most common side effects include dissociation, dizziness, nausea, and increased blood pressure—typically mild to moderate and resolving within hours after administration.
Ketamine infusions may produce similar effects but sometimes with greater intensity due to the IV delivery method and potentially higher dosages. The controlled dosing and nasal administration of Spravato may offer advantages for patients concerned about side effect management.
For a complete overview of potential side effects and how our clinical team manages them, visit our Spravato side effects information page.
Abigail’s Journey: Finding Hope with Spravato
“I had tried everything,” recalls Abigail, a 56-year-old architect from Montclair who came to Spravato Treatment Centers of New Jersey after struggling with treatment-resistant depression for over a decade. Despite trying six different antidepressants and years of therapy, Abigail continued experiencing debilitating depression that impacted her career and personal relationships.
“As a designer, creativity is essential to my work, but depression drained all my inspiration and energy,” she explains. “Some days, I couldn’t even bring myself to open my design software.”
After consulting with our medical director, Abigail began Spravato treatment. Within three weeks, she noticed significant improvements. “The changes weren’t instant magic, but gradually I felt my motivation returning. By the sixth week, colleagues were commenting on how my creative spark had returned.”
Now maintaining her progress with monthly treatments, Abigail has returned to full productivity at her architectural firm. “Spravato didn’t just help my depression—it gave me back my professional identity and passion.”
Making an Informed Treatment Decision
When considering treatment options for depression that hasn’t responded to traditional approaches, understanding these key differences between Spravato and ketamine becomes crucial. The FDA-approved status, controlled administration, and potential insurance coverage make Spravato an attractive option for many patients with treatment-resistant depression.
At Spravato Treatment Centers of New Jersey, our experienced clinical team specializes in guiding patients through the Spravato treatment process. We provide comprehensive evaluations to determine eligibility and develop personalized treatment plans tailored to each individual’s needs.
If you or a loved one continues to struggle with depression despite trying multiple medications, contact us to learn whether Spravato might offer a pathway to relief and recovery.
Author’s Bio
Dr. David Boguslavsky, MD, is a highly experienced family physician and medical acupuncturist with over two decades of clinical practice, who has emerged as a leader in mental health treatment, particularly in the field of depression. A graduate of Robert Wood Johnson Medical School, Dr. Boguslavsky is board-certified in both Family Medicine and Medical Acupuncture, showcasing his diverse medical expertise. His extensive experience spans a wide range of medical care, from acute illnesses to chronic condition management, with a particular focus on preventative care and pain treatment.
Notably, Dr. Boguslavsky has pioneered innovative approaches to depression treatment, having administered over 10,000 Spravato treatments, establishing himself as one of the foremost experts in this cutting-edge therapy. His unique blend of traditional Western medicine, Eastern acupuncture techniques, and advanced psychiatric treatments allows him to offer comprehensive, personalized care to his patients at PremierMD and Spravato Treatment Centers of NJ. Fluent in English and Russian, Dr. Boguslavsky brings a multifaceted approach to healthcare, combining the latest medical technologies with time-honored principles of doctor-patient relationships to address both physical and mental health needs.
David Boguslavsky, MD is an experienced and dedicated family physician and medical acupuncturist who has been practicing medicine for almost two decades. He is a firm believer in complementary medicine, the power of old knowledge, and new technology, and the therapeutic potential of Medical Marijuana and Spravato / esketamine for depression.
